Concurrent facial and trigeminal nerve palsies in a child following COVID-19 vaccination with the Pfizer vaccine.
Carine J MoeziniaEleanor B HarbinsonRobert M MaweniPublished in: BMJ case reports (2023)
We present the case of a teenaged boy who attended our Ear, Nose and Throat Emergency clinic with a left-sided lower motor neuron (LMN) facial nerve paralysis associated with sensory loss in the distribution of the ophthalmic (V1) and maxillary (V2) divisions of the trigeminal nerve. This happened 3 days following a first dose of the Pfizer-BioNTech BNT162b2 vaccine. He had a House-Brackmann grade V facial palsy, with marked inability to close the left eye. He was treated with a 10-day course of oral steroids and referred to ophthalmology for eye care. He had an MRI scan of the head, which revealed no space occupying lesions or other abnormalities. Over the 6-week period of follow-up, the patient's V1 and V2 sensation gradually resolved, along with improvement of his LMN facial nerve palsy to House-Brackmann grade 3. Despite the potential temporal relationship, it is not possible to establish a causal relationship between the patient's symptoms and the Pfizer-BioNTech BNT162b2 vaccine, thus further research is required.
Keyphrases
- peripheral nerve
- soft tissue
- healthcare
- case report
- sars cov
- coronavirus disease
- primary care
- emergency department
- public health
- neuropathic pain
- computed tomography
- mental health
- palliative care
- quality improvement
- clinical trial
- randomized controlled trial
- pain management
- squamous cell carcinoma
- chronic pain
- magnetic resonance
- risk assessment
- spinal cord
- locally advanced
- respiratory syndrome coronavirus
- study protocol
- optical coherence tomography
- optic nerve
- double blind
- rectal cancer